Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 3/20 | 0.56 |
| ▸ | DRD2 | P14416 | 2/20 | 0.55 |
| ▸ | DRD3 | P35462 | 2/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 1/20 | 0.53 |
| ▸ | CCR1 | P32246 | 2/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.53 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2140245 | 0.99 | HTR7 (0.55) | HTR7DRD2DRD3DRD1DRD4 | |
| SCHEMBL5410338 | 0.97 | DRD3 (0.59) | HTR7DRD2DRD3DRD1DRD4 | |
| Hydrochloric Acid SCHEMBL4224036 | 0.96 | DRD3 (0.58) | HTR7DRD2DRD3DRD1DRD4 | |
| SCHEMBL8980793 | 0.96 | DRD3 (0.58) | HTR7DRD2DRD3DRD1DRD4 | |
| Hydrochloric Acid SCHEMBL4218459 | 0.95 | DRD3 (0.58) | HTR7DRD2DRD3DRD1DRD4 | |
| SCHEMBL2138032 | 0.91 | HTR7 (0.57) | HTR7ABCB1POLB | |
| SCHEMBL10035624 | 0.91 | MBTD1 (0.59) | HTR7DRD2DRD3HTR2AABCB1 | |
| SCHEMBL10035555 | 0.91 | ABCB1 (0.54) | HTR7DRD2DRD3DRD1DRD4 | |
| SCHEMBL10035595 | 0.91 | ABCB1 (0.64) | HTR7DRD3DRD4KMT2AHTR2A | |
| SCHEMBL10035603 | 0.90 | HTR7 (0.54) | HTR7DRD2HTR2AHTR2CHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148397-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-04-03 | — | — | US | disclosed |
| US-8148397-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-04-03 | — | — | US | disclosed |
| US-20090088450-A1 | 5-ht7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-04-02 | — | — | US | disclosed |
| US-20090088450-A1 | 5-ht7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088450-A1 | 5-ht7 receptor antagonists | HTR7, HTR1A, HTR5A | HTR7 1/4885DRD2 42/4885DRD3 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.